Apatinib in the treatment of advanced lung adenocarcinoma with KRAS mutation

Activating KRAS mutations in lung adenocarcinoma are characterized with treatment resistance and poor prognosis. As a small molecule inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase, apatinib has been proven successful in advanced gastric cancer and breast cancer....

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Da-xiong, Wang, Chang-guo, Huang, Jian-an, Jiang, Jun-hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584919/
https://www.ncbi.nlm.nih.gov/pubmed/28894382
http://dx.doi.org/10.2147/OTT.S139520

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584919/
https://www.ncbi.nlm.nih.gov/pubmed/28894382
http://dx.doi.org/10.2147/OTT.S139520

Ejemplares similares